LIFEMD INC (LFMD)
US53216B1044 - Common Stock
Overall LFMD gets a fundamental rating of 3 out of 10. We evaluated LFMD against 40 industry peers in the Health Care Technology industry. LFMD may be in some trouble as it scores bad on both profitability and health. LFMD is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
In the past year LFMD has reported negative net income.
LFMD had a positive operating cash flow in the past year.
In the past 5 years LFMD always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: LFMD reported negative operating cash flow in multiple years.
1.2 Ratios
The Return On Assets of LFMD (-43.06%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -43.06% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-117.88%
ROA(5y)-183.33%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
LFMD has a better Gross Margin (88.21%) than 94.87% of its industry peers.
In the last couple of years the Gross Margin of LFMD has grown nicely.
The Profit Margin and Operating Margin are not available for LFMD so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 88.21% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.79%
GM growth 5Y2.59%
2. Health
2.1 Basic Checks
LFMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
LFMD has more shares outstanding than it did 1 year ago.
The number of shares outstanding for LFMD has been increased compared to 5 years ago.
The debt/assets ratio for LFMD is higher compared to a year ago.
2.2 Solvency
LFMD has an Altman-Z score of -0.29. This is a bad value and indicates that LFMD is not financially healthy and even has some risk of bankruptcy.
LFMD has a Altman-Z score (-0.29) which is comparable to the rest of the industry.
LFMD has a debt to FCF ratio of 2.37. This is a good value and a sign of high solvency as LFMD would need 2.37 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 2.37, LFMD belongs to the best of the industry, outperforming 87.18% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 2.37 | ||
| Altman-Z | -0.29 |
ROIC/WACCN/A
WACC10.83%
2.3 Liquidity
LFMD has a Current Ratio of 0.99. This is a bad value and indicates that LFMD is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.99, LFMD is not doing good in the industry: 69.23% of the companies in the same industry are doing better.
A Quick Ratio of 0.94 indicates that LFMD may have some problems paying its short term obligations.
The Quick ratio of LFMD (0.94) is worse than 71.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.99 | ||
| Quick Ratio | 0.94 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 41.27% over the past year.
The Revenue has grown by 32.85% in the past year. This is a very strong growth!
LFMD shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 79.00% yearly.
EPS 1Y (TTM)41.27%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-26.67%
Revenue 1Y (TTM)32.85%
Revenue growth 3Y59.92%
Revenue growth 5Y79%
Revenue growth Q2Q33.26%
3.2 Future
Based on estimates for the next years, LFMD will show a very strong growth in Earnings Per Share. The EPS will grow by 29.78% on average per year.
LFMD is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 28.64% yearly.
EPS Next Y35.4%
EPS Next 2Y29.78%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year36.16%
Revenue Next 2Y28.64%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
LFMD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year LFMD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, LFMD is valued a bit cheaper than the industry average as 71.79% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 41.44 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
LFMD's earnings are expected to grow with 29.78% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.78%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for LFMD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
LIFEMD INC
NASDAQ:LFMD (5/17/2024, 7:10:29 PM)
After market: 7.88 +0.11 (+1.42%)7.77
+0.05 (+0.65%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap317.72M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -43.06% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 88.21% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover2.66
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.99 | ||
| Quick Ratio | 0.94 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)41.27%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y35.4%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)32.85%
Revenue growth 3Y59.92%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y